Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

Vijay K. Yadav, Je Hwang Ryu, Nina Suda, Kenji Tanaka, Jay A. Gingrich, Günther Schütz, Francis H. Glorieux, Cherie Y. Chiang, Jeffrey D. Zajac, Karl L. Insogna, J. John Mann, Rene Hen, Patricia Ducy, Gerard Karsenty

Research output: Contribution to journalArticle

570 Citations (Scopus)

Abstract

Loss- and gain-of-function mutations in the broadly expressed gene Lrp5 affect bone formation, causing osteoporosis and high bone mass, respectively. Although Lrp5 is viewed as a Wnt coreceptor, osteoblast-specific disruption of β-Catenin does not affect bone formation. Instead, we show here that Lrp5 inhibits expression of Tph1, the rate-limiting biosynthetic enzyme for serotonin in enterochromaffin cells of the duodenum. Accordingly, decreasing serotonin blood levels normalizes bone formation and bone mass in Lrp5-deficient mice, and gut- but not osteoblast-specific Lrp5 inactivation decreases bone formation in a β-Catenin-independent manner. Moreover, gut-specific activation of Lrp5, or inactivation of Tph1, increases bone mass and prevents ovariectomy-induced bone loss. Serotonin acts on osteoblasts through the Htr1b receptor and CREB to inhibit their proliferation. By identifying duodenum-derived serotonin as a hormone inhibiting bone formation in an Lrp5-dependent manner, this study broadens our understanding of bone remodeling and suggests potential therapies to increase bone mass.

Original languageEnglish
Pages (from-to)825-837
Number of pages13
JournalCell
Volume135
Issue number5
DOIs
Publication statusPublished - 2008 Nov 28
Externally publishedYes

Fingerprint

Duodenum
Osteogenesis
Serotonin
Bone
Bone and Bones
Osteoblasts
Catenins
Enterochromaffin Cells
Bone Remodeling
Ovariectomy
Osteoporosis
Hormones
Mutation
Enzymes
Genes
Blood
Chemical activation
Therapeutics

Keywords

  • HUMDISEASE
  • SIGNALING

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yadav, V. K., Ryu, J. H., Suda, N., Tanaka, K., Gingrich, J. A., Schütz, G., ... Karsenty, G. (2008). Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Cell, 135(5), 825-837. https://doi.org/10.1016/j.cell.2008.09.059

Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. / Yadav, Vijay K.; Ryu, Je Hwang; Suda, Nina; Tanaka, Kenji; Gingrich, Jay A.; Schütz, Günther; Glorieux, Francis H.; Chiang, Cherie Y.; Zajac, Jeffrey D.; Insogna, Karl L.; Mann, J. John; Hen, Rene; Ducy, Patricia; Karsenty, Gerard.

In: Cell, Vol. 135, No. 5, 28.11.2008, p. 825-837.

Research output: Contribution to journalArticle

Yadav, VK, Ryu, JH, Suda, N, Tanaka, K, Gingrich, JA, Schütz, G, Glorieux, FH, Chiang, CY, Zajac, JD, Insogna, KL, Mann, JJ, Hen, R, Ducy, P & Karsenty, G 2008, 'Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum', Cell, vol. 135, no. 5, pp. 825-837. https://doi.org/10.1016/j.cell.2008.09.059
Yadav, Vijay K. ; Ryu, Je Hwang ; Suda, Nina ; Tanaka, Kenji ; Gingrich, Jay A. ; Schütz, Günther ; Glorieux, Francis H. ; Chiang, Cherie Y. ; Zajac, Jeffrey D. ; Insogna, Karl L. ; Mann, J. John ; Hen, Rene ; Ducy, Patricia ; Karsenty, Gerard. / Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. In: Cell. 2008 ; Vol. 135, No. 5. pp. 825-837.
@article{55c35fd397e84f6ba337d9da04596169,
title = "Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum",
abstract = "Loss- and gain-of-function mutations in the broadly expressed gene Lrp5 affect bone formation, causing osteoporosis and high bone mass, respectively. Although Lrp5 is viewed as a Wnt coreceptor, osteoblast-specific disruption of β-Catenin does not affect bone formation. Instead, we show here that Lrp5 inhibits expression of Tph1, the rate-limiting biosynthetic enzyme for serotonin in enterochromaffin cells of the duodenum. Accordingly, decreasing serotonin blood levels normalizes bone formation and bone mass in Lrp5-deficient mice, and gut- but not osteoblast-specific Lrp5 inactivation decreases bone formation in a β-Catenin-independent manner. Moreover, gut-specific activation of Lrp5, or inactivation of Tph1, increases bone mass and prevents ovariectomy-induced bone loss. Serotonin acts on osteoblasts through the Htr1b receptor and CREB to inhibit their proliferation. By identifying duodenum-derived serotonin as a hormone inhibiting bone formation in an Lrp5-dependent manner, this study broadens our understanding of bone remodeling and suggests potential therapies to increase bone mass.",
keywords = "HUMDISEASE, SIGNALING",
author = "Yadav, {Vijay K.} and Ryu, {Je Hwang} and Nina Suda and Kenji Tanaka and Gingrich, {Jay A.} and G{\"u}nther Sch{\"u}tz and Glorieux, {Francis H.} and Chiang, {Cherie Y.} and Zajac, {Jeffrey D.} and Insogna, {Karl L.} and Mann, {J. John} and Rene Hen and Patricia Ducy and Gerard Karsenty",
year = "2008",
month = "11",
day = "28",
doi = "10.1016/j.cell.2008.09.059",
language = "English",
volume = "135",
pages = "825--837",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

AU - Yadav, Vijay K.

AU - Ryu, Je Hwang

AU - Suda, Nina

AU - Tanaka, Kenji

AU - Gingrich, Jay A.

AU - Schütz, Günther

AU - Glorieux, Francis H.

AU - Chiang, Cherie Y.

AU - Zajac, Jeffrey D.

AU - Insogna, Karl L.

AU - Mann, J. John

AU - Hen, Rene

AU - Ducy, Patricia

AU - Karsenty, Gerard

PY - 2008/11/28

Y1 - 2008/11/28

N2 - Loss- and gain-of-function mutations in the broadly expressed gene Lrp5 affect bone formation, causing osteoporosis and high bone mass, respectively. Although Lrp5 is viewed as a Wnt coreceptor, osteoblast-specific disruption of β-Catenin does not affect bone formation. Instead, we show here that Lrp5 inhibits expression of Tph1, the rate-limiting biosynthetic enzyme for serotonin in enterochromaffin cells of the duodenum. Accordingly, decreasing serotonin blood levels normalizes bone formation and bone mass in Lrp5-deficient mice, and gut- but not osteoblast-specific Lrp5 inactivation decreases bone formation in a β-Catenin-independent manner. Moreover, gut-specific activation of Lrp5, or inactivation of Tph1, increases bone mass and prevents ovariectomy-induced bone loss. Serotonin acts on osteoblasts through the Htr1b receptor and CREB to inhibit their proliferation. By identifying duodenum-derived serotonin as a hormone inhibiting bone formation in an Lrp5-dependent manner, this study broadens our understanding of bone remodeling and suggests potential therapies to increase bone mass.

AB - Loss- and gain-of-function mutations in the broadly expressed gene Lrp5 affect bone formation, causing osteoporosis and high bone mass, respectively. Although Lrp5 is viewed as a Wnt coreceptor, osteoblast-specific disruption of β-Catenin does not affect bone formation. Instead, we show here that Lrp5 inhibits expression of Tph1, the rate-limiting biosynthetic enzyme for serotonin in enterochromaffin cells of the duodenum. Accordingly, decreasing serotonin blood levels normalizes bone formation and bone mass in Lrp5-deficient mice, and gut- but not osteoblast-specific Lrp5 inactivation decreases bone formation in a β-Catenin-independent manner. Moreover, gut-specific activation of Lrp5, or inactivation of Tph1, increases bone mass and prevents ovariectomy-induced bone loss. Serotonin acts on osteoblasts through the Htr1b receptor and CREB to inhibit their proliferation. By identifying duodenum-derived serotonin as a hormone inhibiting bone formation in an Lrp5-dependent manner, this study broadens our understanding of bone remodeling and suggests potential therapies to increase bone mass.

KW - HUMDISEASE

KW - SIGNALING

UR - http://www.scopus.com/inward/record.url?scp=56349162283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349162283&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2008.09.059

DO - 10.1016/j.cell.2008.09.059

M3 - Article

C2 - 19041748

AN - SCOPUS:56349162283

VL - 135

SP - 825

EP - 837

JO - Cell

JF - Cell

SN - 0092-8674

IS - 5

ER -